Helsinki University Licensing Ltd. Oy
Records under this name other than patents Helsinki University Licensing Ltd. Oy holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Helsinki University Licensing Ltd. Oy
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,795,178 | Method and apparatus for analysis of gas compositions Term ended Term ended Dec 6, 2020 · USPTO record | Term ended | Term ended Dec 6, 2020 | USPTO record |
| US 7,947,472 | Expression vectors and cell lines expressing vascular endothelial growth factor D Formerly held Term ended Ended no later than Dec 23, 2018 · USPTO record | Term ended | Ended no later than Dec 23, 2018 | USPTO record |
| US 6,107,192 | Reactive preclean prior to metallization for sub-quarter micron application Formerly held Term ended Term ended Dec 30, 2017 · USPTO record | Term ended | Term ended Dec 30, 2017 | USPTO record |
| US 6,107,046 | Antibodies to Flt4, a receptor tyrosine kinase and uses thereof Formerly held Term ended Term ended Jul 28, 2017 · USPTO record | Term ended | Term ended Jul 28, 2017 | USPTO record |
| US 6,331,301 | Antibodies specific for vascular endothelial growth factor-B Term ended Term ended May 6, 2017 · USPTO record | Term ended | Term ended May 6, 2017 | USPTO record |
| US 6,432,635 | Cystatin B mutants Formerly held Term ended Term ended Mar 18, 2017 · USPTO record | Term ended | Term ended Mar 18, 2017 | USPTO record |
| US 6,130,071 | Vascular endothelial growth factor C (VEGF-C) .DELTA.Cys.sub.156 protein and gene, and uses thereof Formerly held Term ended Term ended Feb 5, 2017 · USPTO record | Term ended | Term ended Feb 5, 2017 | USPTO record |
| US 6,361,946 | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof Formerly held Term ended Term ended Feb 5, 2017 · USPTO record | Term ended | Term ended Feb 5, 2017 | USPTO record |
| US 6,764,820 | Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3) Formerly held Lapsed on the fee record Ended Jul 20, 2016 · USPTO record | Lapsed on the fee record | Ended Jul 20, 2016 | USPTO record |
| US 6,245,530 | Receptor ligand Formerly held Term ended Term ended Jan 12, 2016 · USPTO record | Term ended | Term ended Jan 12, 2016 | USPTO record |